UNASSIGNED: 416 Background: Limited information about real-world treatment patterns of targeted agents for metastatic @entity1358 (mRCC) is available to inform their use in clinical practice. METHODS: This retrospective, observational study employed US claims data (January 2007-November 2010) to identify treatment patterns, including treatment duration and dosing, for targeted agents ( @entity2240 , @entity2857 , @entity6219 , bevacizumab, and @entity13850 ) indicated in 1st line management of advanced/mRCC. The study included adult mRCC @entity1 who were observed for >= 3 months after initiation of their 1st line therapy with a targeted agent. Descriptive analyses were conducted for the observed treatment patterns. RESULTS: A total of 273 @entity1 on 1st line therapy were identified and included in the study sample out of which 235 @entity1 were treated with @entity2240 , 16 @entity1 with @entity2857 , and 15 @entity1 with @entity13850 . @entity6219 and bevacizumab were excluded from further analysis due to their small samples; n<10. The median observed treatment durations were: @entity2240 3.3 months, @entity2857 4.0 months, and @entity13850 2.6 months. @entity1 initiating therapy on @entity2857 (n=16) and @entity13850 (n=15) in the study sample were insufficient for meaningful dosing analyses. In sum, of the n=235 @entity2240 @entity1 , 178 (approximately 76%) initiated therapy at the indicated dose of 50 mg. Sixty-five percent of these @entity1 were not observed filling a 4th script (the average number observed), while 26% maintained their starting dose and 9% experienced a dose reduction at their fourth fill. (See table). CONCLUSIONS: This study suggests that opportunities exist to improve treatment duration in real-world clinical practice and to better understand possible influences, other than disease progression, on treatment and dose changes. [Table: see text].

Treatment patterns: Targeted therapies indicated for first-line management of metastatic XXXX in a real-world setting.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity13850 :: ('MESH:C401859', 'Chemical') :: ['temsirolimus'] @entity6219 :: ('MESH:C516667', 'Chemical') :: ['pazopanib', 'Pazopanib'] @entity2240 :: ('MESH:C473478', 'Chemical') :: ['sunitinib'] @entity2857 :: ('MESH:C471405', 'Chemical') :: ['sorafenib'] @entity1358 :: ('MESH:D002292', 'Disease') :: ['renal cell carcinoma']
@entity1358 :: (MESH:D002292,Disease) :: ['renal cell carcinoma']
